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Introduction
This summary of the 2007 ERA-EDTA Registry Report
includes data on renal replacement therapy (RRT) from 49
national and regional registries in 28 countries in Europe
and bordering the Mediterranean Sea (Figure 1). Data sets
with individual patient data for analysis were received from
34 registries, whereas 17 registries contributed data only in
aggregated form. For both types of registries, we present
incidence and prevalence data as well as transplant rates.
Survival analysis used the data from countries and regions
that provided individual patient records. More detailed data
than those presented in this paper can be found in the 2007
ERA-EDTA Registry Report [1] that is also available on
www.era-edta-reg.org.
The incidence of RRT for ESRD across Europe
In 2007, the overall incidence rate of RRT for end-stage
renal disease (ESRD) among all registries reporting to
the ERA-EDTA Registry was 116 per million population
(pmp). Figure 2 shows that the highest incidence rates
at Day 1 were reported by Turkey (231 pmp), Portugal
(227 pmp) and Israel (193 pmp), whereas incidence rates
below 100 pmp were reported by Ukraine (20 pmp), Rus-
sia (31 pmp), Montenegro (32 pmp), Iceland (81 pmp),
Latvia (86 pmp), Romania (90 pmp), Finland (92 pmp) and
FYR of Macedonia (92 pmp). The mean age at the start
of RRT ranged from 43 years (Ukraine) to 69 years (Bel-
gium) (Figure 2). Table 1 shows the incidence rate of RRT
over the period 2003–2007 for countries and regions pro-
viding individual patient data, adjusted for age and gender
distribution.
Fortheagegroup0–19yearsatthestartofRRT,datawere
available for a limited number of registries including those
of Austria, Denmark, Finland, Greece, Iceland, Norway,
Romania, Spain (Andalusia), Spain (Aragon), Spain
Table 1. Incidence of RRT over the period 2003–2007 per million popu-
lation (pmp) at Day 1, adjusted for age and gender distribution
Country /regions
providing individual 2003 2004 2005 2006 2007
patient data pmp pmp pmp pmp pmp
Austria 138 156 148 153 146
Belgium,
Dutch-speaking
160 163 163 169 161
Belgium,
French-speaking
156 179 171 180 178
Denmark 133 131 119 117 136
F i n l a n d 9 39 49 28 38 5
Greece 168 177 171 172 164
Iceland 83 87 81 79 84
Italy, Calabria 130 137 127 121 132
Norway 97 102 101 101 113
Spain, Andalusia 137 138 141 139 125
Spain, Aragon 87 114 119 93 113
Spain, Asturias 108 132 101 102 103
Spain, Basque country 128 112 107 99 98
Spain, Cantabria 126 135 142 115 99
Spain, Castile and
Leon
98 100 91 101 99
Spain, Castile-La
Mancha
105 113 125 109 102
Spain, Catalonia 144 132 141 125 130
Spain, Valencian
region
148 157 140 144 137
Sweden 113 113 110 117 117
The Netherlands 108 110 109 114 117
United Kingdom,
England
73 86 107 111 107
United Kingdom,
Scotland
117 110 119 109 106
United Kingdom,
Wales
121 112 122 126 129
All countries 111 118 123 124 122
(Basque country), Spain (Catalonia), Spain (Valencian re-
gion), Sweden, The Netherlands, and United Kingdom
(Scotland). As numbers of children starting RRT were
low, we present averages for 2006–2007 (Table 2). In
2007, the ERA-EDTA Registry started a close collabora-
tionwiththeESPN/ERA-EDTARegistrythatinitiateddata
collection from paediatric registries across Europe [2]. For
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Fig. 1. Incidence of RRT per million population (pmp) at Day 1, 2007. B&H = Bosnia–Herzegovina; FYROM = Former Yugoslav Republic of
Macedonia.
Table 2. Incidence of RRT over the period 2006–2007 per million age-
related population (pmarp) per year at Day 1, by age group, unadjusted
0–19 0–4 5–9 10–14 15–19
Cohort pmarp pmarp pmarp pmarp pmarp
2006–2007 10 8 5 8 16
an overview of paediatric RRT data collected from those
registries, please visit www.espn-reg.org.
Table 3 shows the incidence rate of RRT by age group,
for countries and regions providing individual patient data.
For the highest age groups, the highest incidence rates were
reported from Belgium and Greece, whereas Finland and
Romania belong to the countries reporting the lowest inci-
dence rates.
The incidence rates of RRT for ESRD due to diabetes
mellitus were highest in Israel (81 pmp), Turkey (64 pmp),
and Slovakia (60 pmp), whereas the highest incidence rates
of RRT for ESRD due to hypertension/renal vascular dis-
ease were reported from Turkey (58 pmp), and Belgium
(52 pmp) (Table 4).
The prevalence of RRT for ESRD across Europe
The overall prevalence among all registries reporting to
the ERA-EDTA Registry was 662 pmp. Figure 3 shows
that the prevalence of RRT pmp at 31 December 2007 was
highestinPortugal(1372pmp),Belgium(French-speaking)
(1109 pmp) and Spain (Catalonia) (1100 pmp). The lowest
prevalence was reported by Ukraine (85 pmp) and Russia
(146pmp).Themeanageat31December2007rangedfrom
44 years (Russia and Ukraine) to 64 years (Belgium, Dutch
speaking) for registries providing data both on dialysis and
transplant patients (Figure 3). Table 5 shows the overall
prevalenceofRRT,adjustedforageandgenderdistribution.
Only a limited number of registries provided com-
plete data for prevalent patients in the age group 0–
19 years in 2007, including those of Austria, Den-
mark, Finland, Greece, Iceland, Norway, Romania, Spain
(Andalusia), Spain (Aragon), Spain (Basque country),
Spain (Catalonia), Spain (Valencian region), Sweden, The
Netherlands and United Kingdom (Scotland). The preva-
lence for age group 0–19 years is presented in Table 6.516 V . S. Stel et al.
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Fig. 2. Incidence of RRT per million population (pmp) and mean age (years) at Day 1 in 2007, unadjusted. Figures include data from renal registries
providing individual patient data (left figure) and aggregated data (right figure). Data of Estonia and Tunisia are based on Day 91 of RRT.
Table 7shows that for thehighest age groups, the highest
prevalence was reported by Belgium, Greece, Italy, and
several Spanish registries.
Renal transplants
Figure 4 shows that the highest transplant rates were re-
ported from Spain (Cantabria) (71 pmp), Spain (Catalonia)
(65 pmp) and Norway (55 pmp). Countries with the highest
transplant rates with living donor kidneys included Iceland
(23pmp),TheNetherlands(23pmp)andNorway(18pmp).
Patient and graft survival
Survival analysis used the data from 20 registries in 12
countries that provided individual patient records for the
periods 1998–2002 and 2001–2005. Data are presented for
all countries and regions together (Table 8 and Figures 5–
7). Comparisons of survival by treatment modality were all
adjusted for fixed values of age, gender and distribution
of PRD. Similar adjustments have been applied to survival
comparisons by PRD (please, consult appendix for fixed
values and further methodology).
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Fig. 3. Prevalence of RRT per million population (pmp) and mean age (years) on 31 December 2007, unadjusted. Figures include data from renal
registries providing individual patient data (left figure) and aggregated data (right figure). Data from Czech Republic, Israel, Italy (14 of 20 regions),
Slovakia and Tunisia include dialysis patients only, and in Italy (12 of 20 regions) the percentage of missing prevalent RRT patients is estimated at 11%,
due to an estimated 25–30% underreporting of patients living on a functioning graft.
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Appendix: statistical methods
To Table 8
Data presented include the survival of incident patients
on RRT and of patients receiving a first transplant be-
tween 1998–2002 or between 2001–2005 with their 95%
confidence intervals. The patients were followed until
31 December 2007. Statistical analysis of unadjusted sur-
vival was performed by the Kaplan–Meier method.
For the analysis of patient survival on RRT, the day at the
start of RRT was taken as the starting point and the event
studied was death. Censored observations were recovery of
renal function, loss to follow-up and end of follow-up time.518 V . S. Stel et al.
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Fig. 5. Survival of incident dialysis patients and of patients receiving a
first transplant between 1998–2002, by treatment modality, adjusted for
age, gender and primary renal disease.
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Fig. 6. Survival of incident haemodialysis patients in 1998–2002, from
Day 91, by primary renal disease, adjusted for age and gender.The 2007 ERA-EDTA Registry Annual Report—a Pr´ ecis 519
Table 3. Incidence of RRT per million age related population (pmarp) at
Day 1 in 2007, by age group, unadjusted
Country/regions
providing individual 0–19 20–44 45–64 65–74 75+
patient data pmarp pmarp pmarp pmarp pmarp
Austria 10 41 191 488 551
Belgium,
Dutch-speaking
39 171 542 899
Belgium,
French-speaking
34 209 649 848
Denmark 10 51 179 435 524
Finland 11 40 132 231 238
Greece 9 43 188 536 839
Iceland 11 45 137 163 340
Italy (12 of 20
regions)
7 42 143 406 561
Norway 6 42 151 381 416
Romania 8 47 161 251 136
Spain, Andalusia 9 46 160 442 437
Spain, Aragon 9 47 136 490 304
Spain, Asturias 44 141 323 378
Spain, Basque country 3 38 132 340 326
Spain, Cantabria 41 145 362 263
Spain, Castile and
Leon
34 128 378 358
Spain, Castile-La
Mancha
31 145 360 369
Spain, Catalonia 7 44 176 402 523
Spain, Valencian
region
8 51 187 392 582
Sweden 9 44 156 396 428
The Netherlands 10 42 147 393 448
United Kingdom, All
countries
55 154 331 334
United Kingdom,
England
55 153 325 321
United Kingdom,
Northern Ireland
42 141 463 493
United Kingdom,
Scotland
15 59 158 278 317
United Kingdom,
Wales
54 163 435 491
For the analysis of patient survival on dialysis, the first
day on dialysis was the starting point, the event was death
and reasons for censoring were recovery of renal function,
loss to follow-up, end of follow-up time and renal trans-
plantation.
For the analysis of patient and graft survival after trans-
plantation, the date of the first renal transplantation was
defined as the first day of follow-up.
For the patient survival after transplantation, the event
studied was death and for the graft survival the events were
graft failure and death. Reasons for censoring were loss to
follow-up and end of follow-up time.
To Figure 5
For the analyses of patient survival on dialysis the starting
point was Day 91 on dialysis. Analyses were adjusted for
the fixed values of age (60 years), gender (60% men) and
primary renal disease (20% diabetes mellitus, 17% hyper-
tension/renalvasculardisease,15%glomerulonephritisand
48% other cause).
Table 4. IncidenceofRRTpermillionpopulation(pmp)atDay1in2007,
by primary renal disease, unadjusted
Country/regions HT/ Unkn/
providing individual All DM RVD GN Other missing
patient data pmp pmp pmp pmp pmp pmp
Austria 152 48 34 16 37 17
Belgium,
Dutch-speaking
186 44 52 19 56 16
Belgium,
French-speaking
185 42 52 19 64 8
Denmark 141 32 18 15 50 27
Finland 92 32 6 11 24 18
Greece 190 53 22 16 37 62
Iceland 81 10 35 6 26 3
Italy (12 of 20
regions)
150 30 36 16 35 34
Norway 113 15 35 19 40 4
Romania 90 11 6 15 30 28
Spain, Andalusia 121 27 20 16 33 25
Spain, Aragon 130 31 24 24 41 11
Spain, Asturias 133 28 21 10 33 41
Spain, Basque country 113 17 25 12 42 17
Spain, Cantabria 111 19 36 40 12 4
Spain, Castile and
Leon
127 32 22 14 33 26
Spain, Castile-La
Mancha
109 33 14 12 30 20
Spain, Catalonia 137 28 23 19 32 34
Spain, Valencian
region
145 25 37 18 33 32
Sweden 129 35 25 16 38 14
The Netherlands 118 21 26 11 28 32
United Kingdom, All
countries
111 23 12 13 31 32
United Kingdom,
England
109 22 11 12 30 33
United Kingdom,
Northern Ireland
114 26 16 12 44 17
United Kingdom,
Scotland
114 20 13 13 41 27
United Kingdom,
Wales
142 36 15 25 32 34
Bosnia-Herzegovina 164 33 16 14 70 31
Czech Republic
Estonia
France (18 of 24
regions)
139 31 36 16 37 19
FYR of Macedonia 92 21 24 7 21 19
Israel 193 81 19 9 28 57
Italy (14 of 20
regions)
145 29 36 15 33 32
Latvia 86 15 11 11 40 10
Montenegro 32 18 6 3 5
Poland 128 32 17 23 38 17
Portugal
R u s s i a 3 15 2 1 11 1 2
Slovakia 160 60 16 13 63 7
Spain (17 of 19
regions)
126 30 22 16 32 26
Tunisia
Turkey 231 64 58 24 41 45
U k r a i n e 2 03 1 1 06 1
DM: diabetes mellitus; HT: hypertension; RVD: renal vascular disease;
GN: glomerulonephritis/sclerosis; others include pyelonephritis, polycys-
tic kidneys, adult type and miscellaneous; Unkn: unknown.
Categories may not add up because of rounding off.
When cells are left empty, (complete) data are unavailable.520 V . S. Stel et al.
Table 5. Prevalence of RRT on 31 December over the period 2003–2007
per million population (pmp), adjusted for age and gender distribution
Country/region
regions providing 2003 2004 2005 2006 2007
individual patient data pmp pmp pmp pmp pmp
Austria 794 829 854 875 894
Belgium,
Dutch-speaking
848 876 908 939 962
Belgium,
French-speaking
929 978 1010 1054 1087
Denmark 730 751 760 768 798
Finland 642 659 680 686 699
Greece 848 851 872 885 900
Iceland 535 532 527 526 551
Italy, Calabria 897 906 909 913 928
Norway 687 725 743 763 791
Spain, Andalusia 939 968 999 996 981
Spain, Aragon 699 727 755 769 792
Spain, Asturias 765 814 827 835 837
Spain, Basque country 872 902 937 948 965
Spain, Cantabria 722 746 747 745 736
Spain, Castile and
Leon
742 764 776 784 779
Spain, Castile-La
Mancha
865 867 897 900 901
Spain, Catalonia 1007 1037 1028 1028 1060
Spain, Valencian
region
1022 1058 1044 1047 1050
Sweden 753 772 783 804 816
The Netherlands 691 711 736 768 791
United Kingdom,
England
441 538 690 712 742
United Kingdom,
Scotland
707 717 741 759 782
United Kingdom,
Wales
658 663 685 710 780
All countries 686 733 798 815 834
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Fig. 7. Survival of incident peritoneal dialysis patients in 1998–2002,
from Day 91, by primary renal disease, adjusted for age and gender.
Table 6. Prevalence of RRT per million age-related population (pmarp)
on 31 December 2007, by age group, unadjusted
0–19 0–4 5–9 10–14 15–19
Year pmarp pmarp pmarp pmarp pmarp
2007 57 19 38 57 108
Table 7. Prevalence of RRT per million age related population (pmarp)
on 31 December 2007, by age group, unadjusted
Country/regions
providing individual 0–19 20–44 45–64 65–74 75+
patient data pmarp pmarp pmarp pmarp pmarp
Austria 59 461 1558 2417 1829
Belgium,
Dutch-speaking
410 1450 2709 3466
Belgium,
French-speaking
484 1698 3072 3322
Denmark 65 562 1273 1957 1662
Finland 110 432 1237 1559 1220
Greece 50 428 1395 2532 2764
Iceland 68 454 819 1035 1303
Italy (12 of 20
regions)
41 402 1350 2566 3024
Norway 61 494 1308 2054 1618
Romania 21 228 728 825 396
Spain, Andalusia 61 509 1653 2623 2213
Spain, Aragon 30 398 1394 2119 1867
Spain, Asturias 489 1404 2243 1810
Spain, Basque country 122 501 1629 2549 2032
Spain, Cantabria 380 1340 2031 1383
Spain, Castile and
Leon
445 1373 2024 1732
Spain, Castile-La
Mancha
446 1613 2542 1831
Spain, Catalonia 57 467 1775 2967 2800
Spain, Valencian
region
58 480 1705 2913 2966
Sweden 66 488 1439 2063 1610
The Netherlands 68 484 1254 2095 1731
United Kingdom, All
countries
535 1232 1809 1462
United Kingdom,
England
526 1227 1812 1436
United Kingdom,
Northern Ireland
545 1294 2275 2097
United Kingdom,
Scotland
76 620 1253 1683 1259
United Kingdom,
Wales
536 1257 1754 1892
For the analyses of patient survival after transplanta-
tion, the starting point was the time of the first transplant.
The analyses were adjusted for the fixed values of age
(45 years), gender (60% men) and primary renal disease
(10%diabetesmellitus,8%hypertension/renalvasculardis-
ease, 28% glomerulonephritis and 54% other cause).
To Figures 6 and 7
For the analyses presented in each figure, the starting point
was Day 91 on dialysis. The analyses were adjusted for the
fixed values of age (60 years) and gender (60% men).The 2007 ERA-EDTA Registry Annual Report—a Pr´ ecis 521
Table 8. One-, 1- and 5-year survival probabilities, unadjusteda
Cohort 1998–2002 Cohort 2001–2005
1 year 2 years 5 years 1 years 2 years
Patient survival on
RRT
80.9 (80.7–81.2) 69.3 (69.0–69.5) 46.1 (46.0–46.3) 80.9 (80.6–81.1) 69.5 (69.3–69.7)
Patient survival on
dialysis
80.3 (80.0–80.5) 67.2 (67.0–67.5) 38.3 (38.2–38.5) 80.2 (79.9–80.4) 67.6 (67.3–67.8)
Patient survival after
first transplant
(deceased donor)
95.6 (95.3–96.0) 93.7 (93.2–94.1) 86.6 (86.1–87.2) 95.6 (95.3–96.0) 93.7 (93.3–94.0)
Patient survival after
first transplant
(living donor)
97.7 (97.0–98.1) 96.9 (96.2–97.5) 94.0 (93.1–94.7) 97.4 (96.8–97.9) 96.6 (96.0–97.1)
Graft survival after
first transplant
(deceased donor)
90.0 (89.5–90.5) 87.0 (86.5–87.6) 77.5 (76.9–78.1) 90.0 (89.5–90.4) 87.1 (86.5–87.5)
Graft survival after
first transplant
(living donor)
94.4 (93.5–95.2) 92.6 (91.7–93.5) 86.0 (84.9–87.1) 93.8 (93.0–94.5) 92.0 (91.2–92.8)
aFor analysis methods, see the appendix.
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